Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010 Jul; 66(2):345-56.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.